Human orthopneumovirus

Airway Therapeutics Closes $15.5 Million Series C Financing to Advance Preclinical and Clinical Research and Development Programs to Prevent and Treat Serious Respiratory Diseases

Retrieved on: 
Wednesday, January 8, 2020
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Baby, Maternity, Consumer, Medical specialties, Neonatology, RTT, Childhood, Respiratory diseases, Bronchopulmonary dysplasia, Infancy, Human orthopneumovirus, Cystic fibrosis, Preterm birth, Respiratory disease, Lung, AT-100, bronchopulmonary dysplasia, Airway Therapeutics

This funding will enable clinical development of AT-100 (rhSP-D), an investigational preventive treatment for the serious respiratory disease bronchopulmonary dysplasia (BPD) in very preterm infants, while also supporting preclinical research in influenza, respiratory syncytial virus (RSV) and cystic fibrosis.

Key Points: 
  • This funding will enable clinical development of AT-100 (rhSP-D), an investigational preventive treatment for the serious respiratory disease bronchopulmonary dysplasia (BPD) in very preterm infants, while also supporting preclinical research in influenza, respiratory syncytial virus (RSV) and cystic fibrosis.
  • Preclinical research in BPD demonstrated that Airways AT-100 prevented the onset of lung tissue damage, and reduced inflammation and infection triggered by mechanical ventilation and oxygen support.
  • Funding from the Series C financing will enable Airway to further develop its preclinical package for influenza, RSV and cystic fibrosis in preparation for additional clinical trials in 2021.
  • Mr. Patel has more than 25 years of experience covering all aspects of biopharmaceutical clinical development, including program management, clinical operations, regulatory affairs, analytical development and quality.

Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028

Retrieved on: 
Tuesday, December 31, 2019
Medical specialties, Human orthopneumovirus, Paramyxoviridae, RSV, Medicine, Lower respiratory tract infection, Branches of biology, Nucleolin, Mononegavirales, Orthopneumovirus, Palivizumab

DUBLIN, Dec. 31, 2019 /PRNewswire/ -- The "Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 31, 2019 /PRNewswire/ -- The "Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age.
  • The main driver of growth will be the launch of new products to prevent medically-significant Respiratory Syncytial Virus (RSV) infections, including the first products to be licensed for Respiratory Syncytial Virus (RSV) in India and urban China.
  • It is likely that several first-in-class products for the management of Respiratory Syncytial Virus (RSV) will coexist simultaneously by 2028, including both vaccines and antivirals for treatment of severe or breakthrough Respiratory Syncytial Virus (RSV) infections.

Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028

Retrieved on: 
Tuesday, December 24, 2019
Human orthopneumovirus, Paramyxoviridae, RSV, Nucleolin, Mononegavirales, Orthopneumovirus

Respiratory Syncytial Virus (RSV) is also an important cause of hospitalizations and deaths in elderly adults.

Key Points: 
  • Respiratory Syncytial Virus (RSV) is also an important cause of hospitalizations and deaths in elderly adults.
  • The main driver of growth will be the launch of new products to prevent medically-significant Respiratory Syncytial Virus (RSV) infections, including the first products to be licensed for Respiratory Syncytial Virus (RSV) in India and urban China.
  • It is likely that several first-in-class products for the management of Respiratory Syncytial Virus (RSV) will coexist simultaneously by 2028, including both vaccines and antivirals for treatment of severe or breakthrough Respiratory Syncytial Virus (RSV) infections.
  • The latest research report "Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028" helps in answering the following question with regards to Respiratory Syncytial Virus (RSV) and its therapeutic market in Asia Pacific.

Meissa Vaccines Receives FDA Clearance of IND Application for a Phase 1 Clinical Trial of MV-012-968 for Respiratory Syncytial Virus

Retrieved on: 
Thursday, December 5, 2019
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious diseases, Clinical trials, Human orthopneumovirus, Paramyxoviridae, Virology, RSV, Vaccine, Medical specialties, Medicine, Branches of biology, Vaccines, Pediatrics, Novavax

Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has accepted the companys Investigational New Drug (IND) application to proceed with a U.S. clinical trial of MV-012-968, an investigational vaccine for respiratory syncytial virus (RSV).

Key Points: 
  • Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has accepted the companys Investigational New Drug (IND) application to proceed with a U.S. clinical trial of MV-012-968, an investigational vaccine for respiratory syncytial virus (RSV).
  • The company plans to initiate a Phase 1 clinical trial in adults early in 2020 to assess tolerability and immunogenicity of MV-012-968.
  • RSV is a common respiratory virus that usually causes mild, cold-like symptoms, but RSV infections can be serious, especially for infants and older adults.
  • We look forward to beginning our clinical studies to develop a safe and effective RSV vaccine for infants and the elderly.

Asia-Pacific Respiratory Syncytial Virus Market: Epidemiology Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 18, 2019
Health, Infectious diseases, Human orthopneumovirus, Paramyxoviridae, RSV, Branches of biology, Organ systems, Syndromes, Down syndrome, Mononegavirales, Orthopneumovirus, Palivizumab

The "Respiratory Syncytial Virus: Epidemiology Forecast in Asia-Pacific Markets to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Syncytial Virus: Epidemiology Forecast in Asia-Pacific Markets to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old.
  • The Respiratory Syncytial Virus (RSV) Epidemiology Report and Model provide an overview of the risk factors and global trends RSV in the five growth markets (5GM: Japan, Australia, urban China, India, and South Korea).
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.

ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, November 6, 2019
Life sciences, Articles, Biotechnology, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Human orthopneumovirus, RSV, Adma

Presented key ASCENIV data at IDWeek 2019 Key supportive data highlighting the encouraging results of ASCENIV for the treatment of Respiratory Syncytial Virus (RSV) in immunocompromised children were presented at IDWeek 2019.

Key Points: 
  • Presented key ASCENIV data at IDWeek 2019 Key supportive data highlighting the encouraging results of ASCENIV for the treatment of Respiratory Syncytial Virus (RSV) in immunocompromised children were presented at IDWeek 2019.
  • Named Company of the Year by BioFlorida ADMA was recently named Company of the Year by BioFlorida, in recognition of the Companys significant achievements over the past year.
  • ADMA Biologics is a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatments of immunodeficient patients at risk for infection.
  • Actual events or results may differ materially from those described in this document due to a number of important factors.

Ark Biosciences Reports Successful Completion of Phase II Proof-of-Concept Clinical Trial of Ziresovir for Treatment of Infants Hospitalized with Respiratory Syncytial Virus (RSV) Infection

Retrieved on: 
Wednesday, November 6, 2019
Infectious diseases, Children, Hospitals, Clinical trials, Biotechnology, Other Health, Health, Consumer, Pharmaceutical, Viruses, Human orthopneumovirus, Paramyxoviridae, Antiviral drug, Medical specialties, Infection, Health, Mononegavirales, Koronis Pharmaceuticals, Molecular virology

Ark Biosciences, a global biotech company developing innovative therapeutics for viral infection and respiratory diseases, today announced positive topline results of its Phase II proof-of-concept study of Ziresovir (AK0529).

Key Points: 
  • Ark Biosciences, a global biotech company developing innovative therapeutics for viral infection and respiratory diseases, today announced positive topline results of its Phase II proof-of-concept study of Ziresovir (AK0529).
  • For the first time ever, an antiviral agent has proven successful in treating infants hospitalized with Respiratory Syncytial Virus (RSV) infection.
  • In the successfully completed phase II VICTOR (Viral Inhibition in Children for Treatment of RSV) study for the treatment of infants hospitalized with RSV infection, Ziresovir, Ark Biosciences proprietary antiviral, demonstrated a clear dose-dependent clinical efficacy.
  • Through these efforts, Ark Biosciences aims to be a global biotechnology company, discovering and developing innovative drugs for treatment of viral infections and respiratory diseases.

IDT Biologika Awarded New Task Order in the Scope of 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases

Retrieved on: 
Tuesday, November 5, 2019
Science, Biotechnology, Research, Pharmaceutical, Health, Medical devices, Clinical trials, Other Health, Respiratory system, Respiratory tract, Human orthopneumovirus, Rockville, Lung, Branches of biology, Health

Respiratory syncytial virus causes infections of the lungs and respiratory tract that commonly affect children below the age of 2.

Key Points: 
  • Respiratory syncytial virus causes infections of the lungs and respiratory tract that commonly affect children below the age of 2.
  • The development and production activities will be performed at the IDT Biologika Rockville facility in Maryland (USA).
  • Our state-of-the-art manufacturing facility located in Rockville is well positioned to serve the current Task Order requirement.
  • IDT Biologika is a member of the Klocke Group, which is specialized in the contract production and packaging of medications, vaccines and cosmetic products.

Respiratory Syncytial Virus: Epidemiology Forecast in Asia-Pacific Markets to 2028

Retrieved on: 
Monday, November 4, 2019
Medicine, Branches of biology, Health, RSV, Human orthopneumovirus, Disease, Down syndrome, Epidemiology

- The Respiratory Syncytial Virus (RSV) Epidemiology Report and Model provide an overview of the risk factors and global trends RSV in the five growth markets (5GM: Japan, Australia, urban China, India, and South Korea).

Key Points: 
  • - The Respiratory Syncytial Virus (RSV) Epidemiology Report and Model provide an overview of the risk factors and global trends RSV in the five growth markets (5GM: Japan, Australia, urban China, India, and South Korea).
  • - The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.
  • Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Respiratory Syncytial Virus Opportunity Analysis and Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 1, 2019
Health, Pharmaceutical, RSV, Human orthopneumovirus

The "Respiratory Syncytial Virus: Opportunity Analysis and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Syncytial Virus: Opportunity Analysis and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.
  • How will the RSV therapeutic market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2018-2028?
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global RSV therapeutics and prophylactics market.